Previous Close | 0.6950 |
Open | 0.7050 |
Bid | 0.7150 x 30000 |
Ask | 0.7650 x 30000 |
Day's Range | 0.7000 - 0.7050 |
52 Week Range | 0.6800 - 7.0000 |
Volume | |
Avg. Volume | 689 |
Market Cap | 109.833M |
Beta (5Y Monthly) | 2.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CAMBRIDGE, Mass., March 19, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 13, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units ("RSUs") covering 2,063 shares of its co
CAMBRIDGE, Mass., March 05, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.
CAMBRIDGE, Mass., February 28, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update.